Can risk groups accurately predict non-sentinel lymph node metastasis in sentinel lymph node-positive endometrial cancer patients? A Turkish Gynecologic Oncology Group Study (TRSGO-SLN-004).
Adenocarcinoma, Clear Cell
/ secondary
Adult
Aged
Aged, 80 and over
Cystadenocarcinoma, Serous
/ secondary
Endometrial Neoplasms
/ pathology
Female
Follow-Up Studies
Humans
Hysterectomy
Lymph Node Excision
Lymph Nodes
/ pathology
Lymphatic Metastasis
Middle Aged
Neoplasm Micrometastasis
/ diagnosis
Neoplasm Staging
Pelvic Neoplasms
/ secondary
Retrospective Studies
Risk Factors
Sentinel Lymph Node
/ pathology
Sentinel Lymph Node Biopsy
endometrial cancer
lymph node dissection
lymphatic metastasis
sentinel lymph node
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
07
07
2020
revised:
11
10
2020
accepted:
02
11
2020
pubmed:
2
12
2020
medline:
5
3
2021
entrez:
1
12
2020
Statut:
ppublish
Résumé
The purpose of this study was to find out the risk factors associated with non-sentinel lymph node metastasis and determine the incidence of non-sentinel lymph node metastasis according to risk groups in sentinel lymph node (SLN)-positive endometrial cancer patients. Patients who underwent at least bilateral pelvic lymphadenectomy after SLN mapping were retrospectively analyzed. Patients were categorized into low, intermediate, high-intermediate, and high-risk groups defined by ESMO-ESGO-ESTRO. Out of 395 eligible patients, 42 patients had SLN metastasis and 16 (38.1%) of them also had non-SLN metastasis. Size of SLN metastasis was the only factor associated with non-SLN metastasis (p = .012) as 13/22 patients with macrometastasis, 2/10 with micrometastasis and 1/10 with isolated tumor cells (ITCs) had non-SLN metastasis. Although all 4 metastases (1.8%) among the low-risk group were limited to SLNs, the non-SLN involvement rate in the high-risk group was 42.9% and all of these were seen in patients with macrometastatic SLNs. Non-SLN metastasis was more frequent in higher-risk groups and the risk of non-SLN metastasis increased with the size of SLN metastasis. Proceeding to complete lymphadenectomy when SLN is metastatic should further be studied as the effect of leaving metastatic non-SLNs in-situ is not known.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
The purpose of this study was to find out the risk factors associated with non-sentinel lymph node metastasis and determine the incidence of non-sentinel lymph node metastasis according to risk groups in sentinel lymph node (SLN)-positive endometrial cancer patients.
METHODS
METHODS
Patients who underwent at least bilateral pelvic lymphadenectomy after SLN mapping were retrospectively analyzed. Patients were categorized into low, intermediate, high-intermediate, and high-risk groups defined by ESMO-ESGO-ESTRO.
RESULTS
RESULTS
Out of 395 eligible patients, 42 patients had SLN metastasis and 16 (38.1%) of them also had non-SLN metastasis. Size of SLN metastasis was the only factor associated with non-SLN metastasis (p = .012) as 13/22 patients with macrometastasis, 2/10 with micrometastasis and 1/10 with isolated tumor cells (ITCs) had non-SLN metastasis. Although all 4 metastases (1.8%) among the low-risk group were limited to SLNs, the non-SLN involvement rate in the high-risk group was 42.9% and all of these were seen in patients with macrometastatic SLNs.
CONCLUSIONS
CONCLUSIONS
Non-SLN metastasis was more frequent in higher-risk groups and the risk of non-SLN metastasis increased with the size of SLN metastasis. Proceeding to complete lymphadenectomy when SLN is metastatic should further be studied as the effect of leaving metastatic non-SLNs in-situ is not known.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
638-645Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
National Comprehensive Cancer Network, NCCN clinical practice guidelines in oncology: uterine neoplasms, Version 1. 2020. https://www.nccn.org/professionals/physician_gls/pdf/uterine_blocks.pdf. Accessed June 10, 2020.
Rossi EC, Kowalski LD, Scalici J, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol. 2017;18(3):384−392.
Bodurtha Smith AC, Fader AN, Tanner EJ. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216(5):459−476.
Leitao MM, Jr, Zhou QC, Gomez-Hidalgo NR, et al. Patient-reported outcomes after surgery for endometrial carcinoma: prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. Gynecol Oncol. 2020;156(1):147−153.
Bogani G, Murgia F, Ditto A, Raspagliesi F. Sentinel node mapping vs. lymphadenectomy in endometrial cancer: a systematic review and meta-analysis. Gynecol Oncol. 2019;153(3):676−683.
Multinu F, Ducie JA, Eriksson AGZ, et al. Role of lymphadenectomy in endometrial cancer with nonbulky lymph node metastasis: comparison of comprehensive surgical staging and sentinel lymph node algorithm. Gynecol Oncol. 2019;155(2):177−185.
Eriksson AGZ, Ducie J, Ali N, et al. Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion. Gynecol Oncol. 2016;140(3):394−399.
Schiavone MB, Scelzo C, Straight C, et al. Survival of patients with serous uterine carcinoma undergoing sentinel lymph node mapping. Ann Surg Oncol. 2017;24(7):1965−1971.
Buda A, Restaino S, Di Martino G, et al. The impact of the type of nodal assessment on prognosis in patients with high-intermediate and high-risk ESMO/ESGO/ESTRO Group endometrial cancer. A multicenter Italian study. Eur J Surg Oncol. 2018;44(10):1562−1567.
Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010;375(9721):1165−1172.
Eggemann H, Ignatov T, Kaiser K, Burger E, Costa SD, Ignatov A. Survival advantage of lymphadenectomy in endometrial cancer. J Cancer Res Clin Oncol. 2016;142(5):1051−1060.
Sueoka K, Umayahara K, Abe A, et al. Prognosis for endometrial cancer patients treated with systematic pelvic and para-aortic lymphadenectomy followed by platinum-based chemotherapy. Int J Gynecol Cancer. 2015;25(1):81−86.
Touhami O, Trinh XB, Gregoire J, et al. Predictors of non-sentinel lymph node (non-SLN) metastasis in patients with sentinel lymph node (SLN) metastasis in endometrial cancer. Gynecol Oncol. 2015;138(1):41−45.
Kennard JA, Stephens AJ, Ahmad S, et al. Sentinel lymph nodes (SLN) in endometrial cancer: the relationship between primary tumor histology, SLN metastasis size, and non-sentinel node metastasis. Gynecol Oncol. 2019;154(1):53−59.
Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2016;26(1):2−30.
Baiocchi G, Mantoan H, Gonçalves BT, et al. Size of sentinel lymph node metastasis predicts non-sentinel node involvement in endometrial cancer. Ann Surg Oncol. 2019;27(5):1589−1594.
Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373(9658):125−136.
Panici PB, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707−1716.
Cragun JM, Havrilesky LJ, Calingaert B, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005;23(16):3668−3675.
Chan JK, Cheung MK, Huh WK, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer. 2006;107(8):1823−1830.
Monterossi G, Buca D, Dinoi G, et al. Intra-operative assessment of sentinel lymph node status by one-step nucleic acid amplification assay (OSNA) in early endometrial cancer: a prospective study. Int J Gynecol Cancer. 2019;29(6):1016−1020.
Renz M, Marjon N, Devereaux K, Raghavan S, Folkins AK, Karam A. Immediate intraoperative sentinel lymph node analysis by frozen section is predictive of lymph node metastasis in endometrial cancer. J Robot Surg. 2020;14(1):35−40.
Ballester M, Dubernard G, Bats AS, et al. Comparison of diagnostic accuracy of frozen section with imprint cytology for intraoperative examination of sentinel lymph node in early-stage endometrial cancer: results of Senti-Endo study. Ann Surg Oncol. 2012;19(11):3515−3521.
Kim CH, Soslow RA, Park KJ, et al. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int J Gynecol Cancer. 2013;23(5):964−970.
Ballester M, Dubernard G, Lécuru F, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol. 2011;12(5):469−476.
Kosťun J, Pešta M, Sláma J, et al. One-step nucleic acid amplification vs ultrastaging in the detection of sentinel lymph node metastasis in endometrial cancer patients. J Surg Oncol. 2019;119(3):361−369.
Plante M, Stanleigh J, Renaud MC, Sebastianelli A, Grondin K, Grégoire J. Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: does adjuvant treatment matter? Gynecol Oncol. 2017;146(2):240−246.
Karalok A, Turan T, Basaran D, et al. Lymph node metastasis in patients with endometrioid endometrial cancer: overtreatment is the main issue. Int J Gynecol Cancer. 2017;27(4):748−753.
Holloway RW, Abu-Rustum NR, Backes FJ, et al. Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol. 2017;146(2):405−415.